Omar Gonzalez-Camarena, MD
Internal Medicine · El Paso, TXNPI 1780682260
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $3,000 of the $4,848 with a category attached, or 61.9%. Smith+Nephew accounts for 63.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $3,445 and has fallen 93.1% since, to $238 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $48.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$3K
- AstraZeneca$402
- Organogenesis Inc.$200
- AbbVie$188
- Lilly USA, LLC$108
- Bayer$90
- plus $788 from 19 others
What the payments were for
- Food & beverage$1,84838%
- Gifts$3,00062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 7 | $3,071 |
| AstraZeneca | 18 | $402 |
| Organogenesis Inc. | 8 | $200 |
| AbbVie | 9 | $188 |
| Lilly USA, LLC | 6 | $108 |
| Bayer | 5 | $90 |
| Exact Sciences | 5 | $84 |
| Novo Nordisk | 4 | $82 |
| KCI USA, Inc. | 3 | $79 |
| Johnson & Johnson | 5 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Abbott | 4 | $64 |
| Melinta Therapeutics, LLC | 4 | $55 |
| GSK | 3 | $45 |
| Novartis | 2 | $39 |
| Amgen | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Hartmann USA, Inc. | 1 | $15 |
| Medela LLC | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Grafix$3,000
How this compares
$4,848 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 173 | $309,137 |
| JanuviaSitagliptin Phosphate | 134 | $196,094 |
| OzempicSemaglutide | 67 | $110,071 |
| TrulicityDulaglutide | 25 | $50,273 |
| FarxigaDapagliflozin Propanediol | 43 | $43,258 |
| LinzessLinaclotide | 39 | $37,314 |
| EliquisApixaban | 37 | $36,820 |
| JardianceEmpagliflozin | 24 | $28,995 |
| RybelsusSemaglutide | 11 | $27,350 |
| Omega-3 Acid Ethyl Esters | 142 | $22,203 |
| VascepaIcosapent Ethyl | 29 | $22,076 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $21,905 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $15,629 |
| SantylCollagenase Clostridium Hist. | 20 | $14,272 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $13,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $108 | $359,410198 claims |
| Novo NordiskOzempic, Rybelsus | $82 | $137,42178 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $402 | $58,88755 claims |
| AbbVieLinzess, Synthroid | $188 | $39,66457 claims |
| Smith+NephewSantyl | $3,071 | $14,27220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in El Paso
- Mohammed Al-NajjarEl Paso$586K
- Michael AnnabiEl Paso$188K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.